C83.72
Burkitt lymphoma, intrathoracic lymph nodes
Clinical Classification Guidelines
Medical Intelligence & Overview
Burkitt lymphoma is a highly aggressive form of non-Hodgkin lymphoma that primarily affects the lymphatic system. When it involves the intrathoracic lymph nodes—the lymph nodes located within the chest cavity—it presents specific clinical features and treatment considerations. This type of lymphoma is notable for its rapid growth, often requiring prompt medical attention and specialized therapies. The ICD-10 code C83.72 specifically helps in classifying cases where Burkitt lymphoma is found in intrathoracic lymph nodes, aiding in diagnosis, treatment planning, and medical record keeping.
Causes & Symptoms
Clinical Causes: Infection with the Epstein-Barr virus (EBV) is strongly linked, especially in endemic regions. Certain genetic mutations that affect cell growth and division can increase risk. Immunosuppression, such as from HIV infection or immunosuppressive therapy, may promote lymphoma development. Environmental factors like exposure to certain chemicals or radiation have been considered, though their roles are less clear. Geographical factors: endemic forms are common in parts of Africa, where EBV infection is widespread. Family history of lymphoma or other cancers, suggesting a genetic predisposition.
Key Symptoms: Swelling or enlargement of the affected lymph nodes in the chest area. Persistent cough or shortness of breath due to compression of airways or lung tissue. Chest pain or discomfort, often worsening with deep breaths or coughing. Unexplained weight loss and fever, which are common in aggressive lymphomas. Night sweats or fatigue, contributing to overall feeling of malaise. In some cases, symptoms may also be related to compression of nearby structures such as the superior vena cava, leading to swelling in the face and neck.
Diagnostic & Treatment
Diagnosis Path: Physical examination focusing on lymph node clusters and overall health status. Imaging tests such as CT scans or PET scans to identify the extent of lymph node involvement in the thorax. Biopsy of the affected lymph node tissue to confirm the presence of lymphoma cells. Laboratory tests including blood counts and blood chemistry analyses. Molecular and genetic tests to identify characteristic mutations associated with Burkitt lymphoma. Immunophenotyping to determine specific cell markers expressed by the lymphoma cells.
Treatment Protocols: Chemotherapy remains the mainstay of treatment, often involving intensive regimens to target rapidly dividing cancer cells. Targeted therapy options, if applicable, focusing on specific genetic abnormalities. Stem cell transplantation may be considered in some cases, especially if the disease recurs. Supportive care to manage side effects of intensive chemotherapy, including infection prevention and management of nutritional needs. Radiation therapy might be used in certain situations, although its role is limited in cases involving widespread disease. Monitoring and follow-up are critical to evaluate treatment response and detect any signs of recurrence.
Clinical Advice & FAQs
Billing Guidance
Is C83.72 a billable ICD-10 code?
Yes, C83.72 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C83.72?
Clinical documentation must specify the nature of Burkitt lymphoma, intrathoracic lymph nodes and any associated comorbidities for accurate reporting.
Cite this Clinical Reference